酶替代疗法
医学
粘多糖病Ⅱ型
知情同意
制药公司
伦理委员会
担保
溶酶体贮存病
药理学
药品
制药工业
重症监护医学
外科
研究伦理
免疫学
立法
疾病
标签外使用
内科学
制药工业
优先次序
医疗实践
扩展访问
酶
病毒学
出处
期刊:
[Figshare (United Kingdom)]
日期:2026-06-16
标识
DOI:10.6084/m9.figshare.32395449.v1
摘要
Funding The preparation of this review was not supported by any external funding.DeclarationsAuthorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found here.AbstractTividenofusp alfa (tividenofusp alfa-eknm; AVLAYAH™) is an intravenous brain-penetrant enzyme replacement therapy (ERT) being developed by Denali Therapeutics for the treatment of mucopolysaccharidosis type II (MPS II). Also known as Hunter syndrome, MPS II is a rare X-linked recessive lysosomal storage disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS) resulting in accumulation of glycosaminoglycans, heparan sulphate and dermatan sulphate. Consisting of the IDS enzyme fused to a transferrin receptor–binding Fc domain, tividenofusp alfa has been designed to enable distribution of exogenous IDS into both the central nervous system and peripheral tissues. Based on a reduction in cerebrospinal fluid heparan sulphate levels in patients with MPS II treated with tividenofusp alfa in a phase I/II trial, in March 2026 tividenofusp alfa was approved in the USA, under accelerated approval, for the treatment of neurologic manifestations of MPS II when initiated in presymptomatic or symptomatic paediatric patients weighing ≥ 5 kg prior to advanced neurologic impairment. Continued approval for tividenofusp alfa may be contingent upon verification of clinical benefit in a confirmatory trial. Tividenofusp alfa has also been granted Priority Medicine designation by the European Medicines Agency. This article summarises the milestones in the development of tividenofusp alfa leading to this first approval for MPS II.© Springer Nature Switzerland AG 2026
科研通智能强力驱动
Strongly Powered by AbleSci AI